Forosa, 70 mg 4 pcs.

Forose is a non-hormonal specific inhibitor of osteoclastic bone resorption, inhibiting the activity of osteoclasts.

Stimulates osteogenesis, restores positive balance between bone resorption and restoration, increases bone mineral density (regulates phosphorus-calcium exchange), promotes formation of bone tissue with normal histological structure.

Indications

– treatment of osteoporosis in postmenopausal women, incl. to reduce the risk of vertebral compression fractures and femoral neck fractures;
– treatment of osteoporosis in men to prevent fractures;
– treatment of osteoporosis caused by long-term use of corticosteroids.

Pharmacological effect

Forosa is a non-hormonal specific inhibitor of osteoclastic bone resorption, suppressing the activity of osteoclasts.

Stimulates osteogenesis, restores a positive balance between bone resorption and restoration, increases bone mineral density (regulates phosphorus-calcium metabolism), promotes the formation of bone tissue with a normal histological structure.

Active ingredient

Alendronic acid

Composition

1 tab. contains alendronate sodium trihydrate 91.350 mg, which corresponds to the content of alendronic acid 70 mg;

excipients:

microcrystalline cellulose,

silicon dioxide colloidal anhydrous,

croscarmellose sodium,

magnesium stearate;

shell composition:

Luster Clear LC 103 (microcrystalline cellulose, carrageenan, macrogol 8000)

Contraindications

Hypersensitivity, pregnancy, lactation, childhood (safety and effectiveness of use have not been determined).

Restrictions on use

Diseases of the gastrointestinal tract in the acute phase (dysphagia, esophagitis, gastritis, duodenitis, peptic ulcer of the stomach and duodenum), stricture or achalasia of the esophagus, chronic renal failure (with Cl creatinine

Side Effects

From the digestive system: abdominal pain, dyspeptic disorders (constipation or diarrhea, flatulence, nausea, vomiting), dysphagia, heartburn, esophagitis, gastric dystonia, ulceration of the mucous membrane of the mouth, pharynx, esophagus, stomach and duodenum, melena.

From the nervous system: headaches, irritability.

From the musculoskeletal system: pain in bones, muscles and joints; osteonecrosis of the jaw has rarely been observed during treatment with bisphosphonates.

From the organ of vision: uveitis, scleritis.

Allergic reactions: hypersensitivity reactions (including skin hyperemia, urticaria, angioedema).

Other: photosensitivity, asymptomatic transient hypocalcemia and hypophosphatemia.

Interaction

Concomitant use of calcium supplements (including dietary supplements) and antacids impairs the absorption of alendronate. In this regard, it is recommended to take other medications no earlier than 30 minutes after taking Forosa.

NSAIDs (including acetylsalicylic acid) may increase the gastrointestinal side effects of alendronic acid.

Although specific drug interaction studies have not been conducted, the use of alendronate in clinical studies with a large number of commonly used drugs was not accompanied by the development of clinically significant interactions.

Overdose

Symptoms: abdominal pain, dyspeptic disorders, dysphagia, heartburn, esophagitis, gastritis; Hypocalcemia and hypophosphatemia may develop.

Treatment is symptomatic. The use of milk and antacids to bind alendronate is indicated. Due to the risk of damage to the esophagus, vomiting should not be induced and the patient should be in an upright position.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

3 years

Manufacturer

Novartis Neva LLC, Russia